{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:35:35Z","timestamp":1779248135328,"version":"3.51.4"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015028","name":"Kangdong Sacred Heart Hospital, Hallym University","doi-asserted-by":"publisher","award":["2022-02"],"award-info":[{"award-number":["2022-02"]}],"id":[{"id":"10.13039\/501100015028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Investigating long-term trends in glaucoma medication.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>All patients diagnosed with glaucoma and prescribed glaucoma eye drops between 2007 and 2020 in Korea\u2019s Health Insurance Review and Assessment Service database participated in this study. A weight was assigned to each prescription using the reciprocal of the total number of prescriptions received by the individual in that year. The number of patients who received each type of glaucoma eye drop prescription was calculated by summing the weights for each year.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>During the study period, prostaglandin analog eye drop monotherapy was the most frequently given type of glaucoma eye drop prescription. Until 2008, the second most frequently given type of glaucoma eye drop prescription was beta blocker eye drop monotherapy; thereafter, it changed to carbonic anhydrase inhibitor\/beta blocker fixed-combination eye drop monotherapy. The prescription proportion of single-ingredient glaucoma eye drops decreased (-1.290%\/year, <jats:italic>P<\/jats:italic> &lt; 0.001), whereas that of fixed-combination glaucoma eye drops increased (1.291%\/year, <jats:italic>P<\/jats:italic> &lt; 0.001). The number of glaucoma eye drops prescribed per patient remained constant (-0.00030\/year, <jats:italic>P<\/jats:italic> = 0.167) with an average of 1.302, while the number of active ingredients prescribed per patient increased (0.01737\/year, <jats:italic>P<\/jats:italic> &lt; 0.001) from 1.659 in 2007 to 1.896 in 2020.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Over 14 years, there was no change in the number of glaucoma eye drops prescribed to individual patients in Korea. However, the number of active ingredients prescribed increased owing to the increased prescription of fixed-combination eye drops. The current trends in glaucoma medication are expected to help establish future treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0305619","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T17:49:27Z","timestamp":1720720167000},"page":"e0305619","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-9162","authenticated-orcid":true,"given":"Kyeong Ik","family":"Na","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won June","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn Joo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-0311","authenticated-orcid":true,"given":"Sung Pyo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"4","key":"pone.0305619.ref001","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","article-title":"Definition of glaucoma: clinical and experimental concepts.","volume":"40","author":"RJ Casson","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"pone.0305619.ref002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"MA Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"pone.0305619.ref003","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"A Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"pone.0305619.ref004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"18","key":"pone.0305619.ref005","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"RN Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"pone.0305619.ref006","doi-asserted-by":"crossref","first-page":"e0227595","DOI":"10.1371\/journal.pone.0227595","article-title":"Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.","volume":"15","author":"L Yu","year":"2020","journal-title":"PLoS One."},{"issue":"3","key":"pone.0305619.ref007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/IJG.0000000000001414","article-title":"Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017","volume":"29","author":"N Perera","year":"2020","journal-title":"J Glaucoma"},{"key":"pone.0305619.ref008","doi-asserted-by":"crossref","first-page":"7642049","DOI":"10.1155\/2017\/7642049","article-title":"Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database.","volume":"2017","author":"M Sakamoto","year":"2017","journal-title":"J Ophthalmol."},{"issue":"5","key":"pone.0305619.ref009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IJG.0b013e31829ea2e6","article-title":"The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007","volume":"24","author":"JC Lin","year":"2015","journal-title":"J Glaucoma"},{"issue":"20","key":"pone.0305619.ref010","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"A. World Medical","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"pone.0305619.ref011","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2010.10.016","article-title":"Prevalence of primary open-angle glaucoma in central South Korea the Namil study","volume":"118","author":"CS Kim","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0305619.ref012","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ophtha.2015.11.004","article-title":"Prevalence, Awareness, and Risk Factors of Primary Open-Angle Glaucoma: Korea National Health and Nutrition Examination Survey 2008\u20132011","volume":"123","author":"KE Kim","year":"2016","journal-title":"Ophthalmology"},{"issue":"Pt 5","key":"pone.0305619.ref013","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/eye.2000.197","article-title":"Compliance and viewpoint of glaucoma patients in Greece.","volume":"14","author":"AG Konstas","year":"2000","journal-title":"Eye (Lond)."},{"issue":"6","key":"pone.0305619.ref014","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review","volume":"112","author":"CM Olthoff","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0305619.ref015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.icu.0000156139.05323.26","article-title":"Compliance and persistency in glaucoma follow-up treatment.","volume":"16","author":"GF Schwartz","year":"2005","journal-title":"Curr Opin Ophthalmol"},{"key":"pone.0305619.ref016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","article-title":"Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%\/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial","volume":"176","author":"HS Barnebey","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0305619.ref017","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/jop.2011.0057","article-title":"Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%\/timolol maleate 0.5% fixed combination","volume":"27","author":"K Inoue","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"pone.0305619.ref018","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-021-01813-w","article-title":"Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare\/pharmacy claims database: a retrospective non-interventional cohort study.","volume":"21","author":"C Shirai","year":"2021","journal-title":"Bmc Ophthalmol."},{"issue":"9","key":"pone.0305619.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093137","article-title":"Fixed versus Unfixed Combination of Topical Latanoprost\/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health.","volume":"12","author":"V Toumanidou","year":"2023","journal-title":"J Clin Med."},{"issue":"4","key":"pone.0305619.ref020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2710.2004.00574.x","article-title":"Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol\u2014a randomized controlled trial and a replacement study.","volume":"29","author":"BA Francis","year":"2004","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"pone.0305619.ref021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ajo.2003.11.020","article-title":"Topical prostaglandin F(2alpha) analog induced poliosis.","volume":"137","author":"CS Chen","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"pone.0305619.ref022","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9394(03)01075-4","article-title":"Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost","volume":"137","author":"J Hart","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0305619.ref023","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0008-4182(02)80004-7","article-title":"Quantitative analysis of eyelash lengthening following topical latanoprost therapy","volume":"37","author":"M Sugimoto","year":"2002","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"pone.0305619.ref024","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0002-9394(00)00402-5","article-title":"Increased eyelid pigmentation associated with use of latanoprost","volume":"129","author":"MS Kook","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0305619.ref025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","article-title":"Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost","volume":"55","author":"J Park","year":"2011","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"pone.0305619.ref026","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/01.opx.0000141791.16683.4a","article-title":"Deepening of lid sulcus from topical bimatoprost therapy.","volume":"81","author":"LS Peplinski","year":"2004","journal-title":"Optom Vis Sci."},{"issue":"4","key":"pone.0305619.ref027","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jaapos.2009.04.017","article-title":"Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial.","volume":"13","author":"DA Plager","year":"2009","journal-title":"J AAPOS"},{"issue":"1","key":"pone.0305619.ref028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1091-8531(98)90109-4","article-title":"Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.","volume":"2","author":"M Portellos","year":"1998","journal-title":"J AAPOS"},{"issue":"8","key":"pone.0305619.ref029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/IJG.0b013e31824d1e2f","article-title":"A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital","volume":"22","author":"L Chang","year":"2013","journal-title":"J Glaucoma"},{"issue":"5","key":"pone.0305619.ref030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/IJG.0b013e31818624e5","article-title":"Exposure to topical apraclonidine in children with glaucoma","volume":"18","author":"TM Wright","year":"2009","journal-title":"J Glaucoma"},{"issue":"5","key":"pone.0305619.ref031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mpa.2001.117571","article-title":"Safety and efficacy of brimonidine in children with glaucoma.","volume":"5","author":"LB Enyedi","year":"2001","journal-title":"J AAPOS."},{"issue":"8","key":"pone.0305619.ref032","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/PL00008324","article-title":"Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma","volume":"158","author":"E Korsch","year":"1999","journal-title":"Eur J Pediatr"},{"issue":"2","key":"pone.0305619.ref033","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0002-9394(99)00083-5","article-title":"Apparent central nervous system depression in infants after the use of topical brimonidine","volume":"128","author":"JO Carlsen","year":"1999","journal-title":"Am J Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T17:49:47Z","timestamp":1720720187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305619"}},"subtitle":[],"editor":[{"given":"Nader Hussien Lotfy","family":"Bayoumi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305619","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}